Agios Pharmaceuticals (AGIO) Expected to Post Earnings on Thursday

Agios Pharmaceuticals (NASDAQ:AGIO) is expected to post its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Agios Pharmaceuticals to announce earnings of ($1.24) per share and revenue of $51.65 million for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:00 AM ET.

Agios Pharmaceuticals Stock Down 2.0%

AGIO stock opened at $29.95 on Tuesday. Agios Pharmaceuticals has a twelve month low of $22.24 and a twelve month high of $46.00. The company has a market cap of $1.79 billion, a PE ratio of -4.27 and a beta of 0.63. The business’s 50-day simple moving average is $33.56 and its 200 day simple moving average is $31.71.

Analysts Set New Price Targets

Several research firms have commented on AGIO. HC Wainwright assumed coverage on Agios Pharmaceuticals in a report on Thursday, October 29th. They issued a “buy” rating and a $55.00 price target for the company. Weiss Ratings reissued a “sell (d)” rating on shares of Agios Pharmaceuticals in a report on Monday, September 21st. Bank of America lifted their price objective on Agios Pharmaceuticals from $46.00 to $50.00 and gave the stock a “buy” rating in a report on Monday, September 21st. TD Cowen upgraded Agios Pharmaceuticals to a “strong-buy” rating in a research report on Monday, August 24th. Finally, Citigroup upped their target price on Agios Pharmaceuticals from $46.00 to $52.00 and gave the company a “buy” rating in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $41.50.

Insider Activity at Agios Pharmaceuticals

In other news, insider Sarah Gheuens sold 7,866 shares of the firm’s stock in a transaction dated Monday, October 26th. The shares were sold at an average price of $37.69, for a total transaction of $296,469.54. Following the completion of the transaction, the insider directly owned 54,645 shares of the company’s stock, valued at approximately $2,059,570.05. This trade represents a 12.58% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 9,855 shares of company stock worth $371,112. 5.40% of the stock is currently owned by company insiders.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for rare diseases involving cellular metabolism. The company’s research is centered on metabolic pathways that influence red blood cell production and function, with the goal of addressing conditions that have limited treatment options.

Agios’ principal commercial product is Pyrukynd (mitapivat), an oral activator of pyruvate kinase. Pyrukynd is approved in the United States and other markets for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency, a rare inherited blood disorder.